The work, led by a joint IPLA-University of Oviedo research group and the company Microviable Therapeutics, with Susana Delgado, from IPLA-CSIC, as the responsible researcher, has managed to identify and select bacteria in the microbiota [...]
Microviable Therapeutics will be presenting at Farmaforum 2023 taking place on September 20th-21th at Madrid. The Microviable team will consist of Claudio Hidalgo, CEO of the company, and Noelia Martínez, R&D Director. Noelia Martínez will [...]
Microviable Therapeutics will be presenting at the Microbiome & Probiotic R&D & Business Collaboration Forum taking place on May 23rd-24th at Rotterdam. Noelia Martínez, R&D Director, Pilar Manrique, Research Scientist and Marta F. Gosende, Research [...]
Microviable Therapeutics is thrilled to announce that will be attending the Microbiome & Probiotic R&D & Business Collaboration Forum taking place on May 23rd-24th at Rotterdam. The event will bring together academic, industry, and investment [...]
Microviable Therapeutics announced the appointment of Dr. Luis Gosálbez as a member of its Business Advisory Board. Gosálbez brings 10 years of experience in business strategy and corporate development for life sciences companies specialized in [...]
Microviable Therapeutics will be presenting at XIV Workshop of SEMiPYP (Spanish Society of Microbiota, Probiotics and Prebiotics) taking place on March 8th-10th at Pamplona. Claudio Hidalgo, CEO at Microviable, Noelia Martínez, R&D Director, and Ignacio [...]
Microviable Therapeutics will be attending the XIV Workshop of SEMiPYP (Spanish Society of Microbiota, Probiotics and Prebiotics) taking place on March 8th-10th at Pamplona. The event will make special mention of the new advances in [...]
Marta has a degree in Biology (2014) and a Food Biotechnology Master (2016) at the University of Oviedo, plus a MS in Microbiota, Probiotics and Prebiotics at the European University at Madrid (2021) with MS [...]
Meet our research intern Carlos Martínez, who is working with us on his Master´s Thesis as part of the Microbiota, Probiotics and Prebiotics Master from the European University of Madrid.
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]